Milestone Scientific Announces Commercial Rollout of CompuFlo® Epidural System at Advanced Spine and Pain Management Following Successful Pilot with Dr. Varinder Dhillon
MWN-AI** Summary
Milestone Scientific Inc. (NYSE: MLSS), recognized for its innovative computerized drug delivery technologies, has announced the successful commercial launch of its CompuFlo® Epidural System at Advanced Spine and Pain Management, LLC. This move comes after a successful pilot program headed by Dr. Varinder Dhillon, whose insights confirm the system's effectiveness in improving patient safety and procedural efficiency.
The Advanced Spine and Pain Management clinic operates out of SurgiCore Montvale, part of a larger network of centers throughout the New York/New Jersey metropolitan area, presenting significant opportunities for future expansion. Following recent Medicare price assignments, the adoption of the CompuFlo® Epidural System is reportedly on the rise, reflecting its clinical and economic advantages.
Utilizing patented Dynamic Pressure Sensing Technology®, the CompuFlo® Epidural System offers real-time feedback that ensures accurate needle placement during epidural procedures. This cutting-edge technology markedly lowers the risk of complications compared to traditional methods, prioritizing patient safety and enhancing overall procedural efficiency.
Dr. Dhillon expressed enthusiasm over the integration of the CompuFlo® Epidural System into clinical practice, stating that its precision and reliability have revolutionized the approach to epidural procedures, resulting in safer and more comforting care for patients.
Neal Goldman, Milestone's Chairman and Interim CEO, noted that the adoption of this advanced technology by Dr. Dhillon demonstrates Milestone's growing presence within the healthcare sector. The increasing acceptance across pain management clinics indicates a positive trajectory for Milestone's business operations and underscores its commitment to innovative healthcare solutions.
Milestone Scientific continues to focus on advancing next-generation medical technology aimed at enhancing the delivery of injections, with a particular emphasis on patient comfort and safety.
MWN-AI** Analysis
The recent announcement from Milestone Scientific Inc. regarding the commercial rollout of the CompuFlo® Epidural System at Advanced Spine and Pain Management represents a significant opportunity for investors to consider. The clinical insights provided by Dr. Varinder Dhillon, bolstered by a successful pilot program, emphasize the system's advantages in patient safety and procedural efficiency.
Milestone Scientific's patented Dynamic Pressure Sensing Technology® is a game-changer in the pain management space, particularly in minimizing complications that often accompany traditional epidural procedures. The increased adoption of this technology, especially following Medicare pricing assignments, signals a positive shift in the market's acceptance of innovative medical solutions. This adoption can lead to higher revenue streams and broader market penetration.
Given that Advanced Spine and Pain Management is part of the larger SurgiCore network, there appears to be ample room for growth. If Milestone can capitalize on this success and expand its footprint within similar clinics across the New York/New Jersey area and beyond, it would potentially enhance its scalability and revenue growth.
However, investors should remain cautious and aware of the various risks articulated in the latest press release. The competitive landscape, regulatory changes, and operational uncertainties are notable factors that could impact the company’s performance.
The current stock price and general market conditions should be considered before making investment decisions. A sustained focus on operational performance and successful marketing of its technologies will be critical for Milestone to maintain investor confidence and achieve long-term growth.
As Milestone Scientific continues to evolve, monitoring their adoption rates and financial performance would be wise. Overall, the potential of the CompuFlo® Epidural System merits attention, positioning Milestone as a noteworthy player in the medical technology sector.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
ROSELAND, N.J., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS) , a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced the commercial rollout of its CompuFlo® Epidural System at Advanced Spine and Pain Management, LLC, a premier pain management clinic. This rollout follows a successful pilot program conducted with Dr. Varinder Dhillon, whose expertise and feedback validate the clinical benefits of the CompuFlo® Epidural System in enhancing patient safety and procedural efficiency.
Advanced Spine and Pain Management operates out of SurgiCore Montvale, one of 12 SurgiCore centers located in the New York/New Jersey metropolitan area, highlighting the opportunity for further expansion within the SurgiCore network. In addition, the Company reports increasing adoption of the CompuFlo® Epidural System following the previously announced Medicare price assignment, reflecting its clinical and economic benefits.
The CompuFlo® Epidural System, utilizing Milestone Scientific’s patented Dynamic Pressure Sensing Technology®, provides real-time feedback to confirm accurate needle placement during epidural procedures. This innovative technology significantly reduces the risk of complications associated with traditional techniques, enhancing both patient safety and procedural efficiency.
Dr. Dhillon commented, "The CompuFlo® Epidural System has transformed the way we approach epidural procedures. The technology’s precision and reliability enable us to deliver safer and more comfortable care to our patients, while also improving procedural efficiency. I am thrilled integrate it into my workflow at Advanced Spine and Pain Management, and am confident it will continue to deliver outstanding results."
Neal Goldman, Chairman and Interim Chief Executive Officer of Milestone Scientific, stated, "The adoption of the CompuFlo® Epidural System by Dr. Dhillon at Advanced Spine and Pain Management illustrates our traction within the healthcare community. With the recent Medicare price assignment, we are witnessing increased adoption of the CompuFlo Epidural System across pain management clinics and other healthcare facilities nationwide."
About Milestone Scientific Inc.
Milestone Scientific Inc. (MLSS), a technology focused medical research and development company that patents, designs and develops innovative injection technologies and instruments for medical and dental applications. Milestone Scientific’s computer-controlled systems are designed to make injections precise, efficient and increase the overall patient comfort and safety. Their proprietary DPS Dynamic Pressure Sensing Technology ® instruments is the platform to advance the development of next-generation devices, regulating flow rate and monitoring pressure from the tip of the needle, through platform extensions of subcutaneous drug delivery, including local anesthetic. To learn more, view the MLSS brand video or visit milestonescientific.com .
Safe Harbor Statement
This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues, timing of regulatory approvals and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions, future business decisions and regulatory developments, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2023 . The forward-looking statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.
Contact:
Crescendo Communications, LLC
Email: mlss@crescendo-ir.com
Tel: 212-671-1020
FAQ**
How does the adoption of the CompuFlo® Epidural System by Advanced Spine and Pain Management signal potential growth for Milestone Scientific Inc. MLSS within the healthcare sector?
What specific clinical benefits has Dr. Varinder Dhillon observed from using Milestone Scientific Inc. MLSS's CompuFlo® Epidural System in terms of patient safety and procedural efficiency?
With the recent Medicare price assignment supporting Milestone Scientific Inc. MLSS, what are the expected financial implications for the company and its expansion plans in the healthcare market?
How does Milestone Scientific Inc. MLSS plan to leverage the traction gained from the CompuFlo® Epidural System to further enhance its market presence and product offerings in the medical device industry?
**MWN-AI FAQ is based on asking OpenAI questions about Milestone Scientific Inc. (NYSE: MLSS).
NASDAQ: MLSS
MLSS Trading
5.09% G/L:
$0.2952 Last:
18,932 Volume:
$0.2816 Open:
